NCT05754047

Tumor Characteristics and Survival Rate of HER2-Low Breast Cancer Patients

Tumor Characteristics and Survival Rate of HER2-Low Breast Cancer Patients; a Cross-Sectional Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 3,582 (actual)
• Sponsor: Mahdis Bayat · Academic / Other
• Sex: Female
• Age: —
• Healthy volunteers: Not accepted

Summary

In this large-scale cross-sectional study, we evaluated disease-free survival (DFS), overall survival (OS), and clinicopathological characteristics of BC patients from 1991 to 2022, retrospectively. We recruited patients referred to the Cancer Research Center in Tehran, Iran, and their HER2 status, which is classified as HER2-low, HER2-positive, or HER2-negative, was obtained from prospectively maintained registries. we aimed to dive more deeply into the clinicopathological characteristics and survival features of HER2-low breast cancer patients and campared it with HER2-negative and HER2-positive groups. Question 1: Is HER2-low breast cancer (BC) a new subtype in the standard classification of BCs? Question 2: How is the DFS and OS rate of HER2-low breast cancer patients in comparison with HER2-negative and HER2-positive groups?

Conditions

• HER2 Low Breast Carcinoma

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	immunohistochemistry (IHC) and in situ hybridization (ISH) Test	These tests are usually applied for breast cancer patients to assist the surgeon to better understand the clinicopathological characteristics and survival features of tumors

Timeline

• Start date: 1991-04-01
• Primary completion: 2022-03-01
• Completion: 2022-03-01
• First posted: 2023-03-03
• Last updated: 2023-03-03